Skip to search formSkip to main contentSkip to account menu

NSC-122819

Known as: NSC 122819, NSC122819 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Teniposide

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1978
1978
VM26 (NSC-122819): a clinical study in advanced cancer of the lung and ovary.
1976
1976
Phase I-II trial of VM-26 (NSC-122819) in the treatment of children with late-stage leukemia.
1976
1976
Phase I-II trial of VM-26 (NSC-122819) in the treatment of children with late-stage leukemia.
1975
1975
4'-demethylepipodophyllotoxin 9-(4,6-o-2-thenylidene-beta-D-glucopyranoside) (NSC-122819; VM-26) and 4'-demethylepipodophyllotoxin 9-(4.6-0-ethylidene-beta-D-glucopyranoside) (NSC-141540; VP-16-213…
We evaluated the responses of 39 children with cancer who, after failure to respond to conventional chemotherapeutic agents… 
1974
1974
Experience with 4'-demethylepipodo-phyllotoxin 9-(4,6-o-2-thenylidene-beta-D-glucopyranoside); VM-26; NSC-122819 in the treatment of malignant lymphosis.
1973
1973
Delayed toxicity of 4'-demethylepipodophyllotoxin 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside) (NSC-122819; VM-26) in mice.
Highly Cited
1972
Highly Cited
1972
Clinical investigation of a new podophyllum derivative, epipodophyllotoxin, 4'-demethyl-9-(4,6-O-2-thenylidene- -D-glucopyranoside) (NSC-122819), in patients with malignant lymphomas and solid tumors…
1971
1971
Clinical studies with a new podophyllotoxin derivative, epipodophyllotoxin, 4'-demethyl-9-(4,6-O-2-thenylidine- -D-glucopyranoside) (NSC-122819).
1971
1971
Clinical studies with a new podophyllotoxin derivative, epipodophyllotoxin, 4'-demethyl-9-(4,6-O-2-thenylidine- -D-glucopyranoside) (NSC-122819).
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)